| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, Mass.—Aileron Therapeutics Inc. recently secured the second tranche in its Series D financing, bringing thetotal round to $42 million.
 
The payment of the second tranche was based on the successfulprogression through preclinical studies of Aileron's lead stapled peptide drug, ALRN-5281. Proceeds from this tranche will be directed tothe clinical development of ALRN-5281 in patients with orphan endocrinedisorders early this year. Once it is set into motion, the ALRN-5281 clinical trialwill mark the first-ever stapled peptide human clinical trial.
 
Current investors Apple Tree Partners, ExcelVenture Management, Lilly Ventures, Novartis Venture Funds, RocheVenture Fund and SR One participated in the round.
 
"These proceeds will allow us to advance ALRN-5281 through Phase Idevelopment and continue to develop our pipeline of stapled peptidedrugs," said Joseph A. Yanchik III, president and chief executiveofficer of Aileron Therapeutics. "This is a critical next step for ourcompany, our collaborators and the emerging stapled peptide field. Weappreciate the continued support of our investors and look forward tosharing more details around our orphan endocrine disorders program whenwe initiate the Phase I study in the coming months."
 
ALRN-5281 was discovered and developedthrough Aileron's stapled peptide technology platform, an approach thatlocks peptides into their biologically active shape "that providesfirst-in-class pharmacokinetic profiles allowing effective delivery ofthe peptide and pharmacological profiles that resemble the naturalproteins." In preclinical studies, ALRN-5281 reportedly has demonstrated propertiesof a stable, long-acting hormone that may overcome the pharmacokineticand dosing challenges that have limited the use and safety oftraditional peptide hormones. 
 
Aileron is also advancing stapled peptide drug candidates incollaboration with Roche, including a highly potent and specific dualinhibitor of MDM2 and MDMX for p53-dependent cancers. Preclinical datafrom this second program were recently presented at the 2012EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
 
SOURCE: Aileron Therapeuticsnews release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue